A detailed history of Barclays PLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 276,610 shares of ARWR stock, worth $5.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
276,610
Previous 276,610 -0.0%
Holding current value
$5.4 Million
Previous $5.36 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$19.36 - $29.54 $3.24 Million - $4.95 Million
167,556 Added 153.64%
276,610 $5.36 Million
Q2 2024

Aug 14, 2024

SELL
$21.87 - $28.24 $2.5 Million - $3.22 Million
-114,094 Reduced 51.13%
109,054 $2.84 Million
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $3.78 Million - $5.48 Million
-138,809 Reduced 38.35%
223,148 $6.38 Million
Q4 2023

Feb 15, 2024

BUY
$21.2 - $31.03 $3.48 Million - $5.1 Million
164,234 Added 83.06%
361,957 $11.1 Million
Q3 2023

Nov 07, 2023

SELL
$26.2 - $36.08 $4.17 Million - $5.74 Million
-159,158 Reduced 44.6%
197,723 $5.31 Million
Q2 2023

Aug 03, 2023

BUY
$25.16 - $41.38 $1.03 Million - $1.69 Million
40,899 Added 12.94%
356,881 $12.7 Million
Q1 2023

May 04, 2023

SELL
$23.68 - $38.51 $549,352 - $893,393
-23,199 Reduced 6.84%
315,982 $8.03 Million
Q4 2022

Feb 13, 2023

BUY
$28.0 - $40.56 $1.14 Million - $1.66 Million
40,884 Added 13.71%
339,181 $13.8 Million
Q3 2022

Nov 03, 2022

BUY
$29.63 - $48.31 $3.16 Million - $5.15 Million
106,537 Added 55.56%
298,297 $9.86 Million
Q2 2022

Aug 12, 2022

BUY
$27.79 - $50.61 $1.27 Million - $2.32 Million
45,851 Added 31.42%
191,760 $6.75 Million
Q1 2022

May 16, 2022

SELL
$39.62 - $69.97 $4.81 Million - $8.5 Million
-121,413 Reduced 45.42%
145,909 $6.71 Million
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $2.9 Million - $4.12 Million
49,938 Added 22.97%
267,322 $17.7 Million
Q3 2021

Nov 09, 2021

BUY
$58.38 - $84.96 $602,189 - $876,362
10,315 Added 4.98%
217,384 $13.6 Million
Q2 2021

Aug 13, 2021

SELL
$62.15 - $90.32 $1.08 Million - $1.57 Million
-17,366 Reduced 7.74%
207,069 $17.1 Million
Q1 2021

May 13, 2021

BUY
$61.35 - $90.47 $3.68 Million - $5.43 Million
60,039 Added 36.52%
224,435 $14.9 Million
Q4 2020

Feb 11, 2021

SELL
$43.82 - $85.37 $1.51 Million - $2.95 Million
-34,567 Reduced 17.37%
164,396 $12.6 Million
Q3 2020

Nov 12, 2020

BUY
$33.21 - $51.27 $114,275 - $176,420
3,441 Added 1.76%
198,963 $8.57 Million
Q2 2020

Aug 12, 2020

BUY
$26.12 - $43.27 $250,072 - $414,266
9,574 Added 5.15%
195,522 $8.45 Million
Q1 2020

May 13, 2020

BUY
$20.56 - $63.12 $886,855 - $2.72 Million
43,135 Added 30.2%
185,948 $5.35 Million
Q4 2019

Feb 10, 2020

BUY
$28.14 - $73.01 $907,965 - $2.36 Million
32,266 Added 29.19%
142,813 $9.06 Million
Q3 2019

Nov 14, 2019

SELL
$26.26 - $34.86 $199,129 - $264,343
-7,583 Reduced 6.42%
110,547 $3.12 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $847,028 - $1.4 Million
48,596 Added 69.89%
118,130 $3.13 Million
Q1 2019

May 15, 2019

BUY
$12.05 - $20.18 $688,886 - $1.15 Million
57,169 Added 462.35%
69,534 $1.28 Million
Q4 2018

Feb 14, 2019

SELL
$10.74 - $19.7 $461,658 - $846,804
-42,985 Reduced 77.66%
12,365 $153,000
Q3 2018

Nov 14, 2018

SELL
$14.0 - $20.3 $123,228 - $178,680
-8,802 Reduced 13.72%
55,350 $1.06 Million
Q2 2018

Aug 14, 2018

SELL
$6.37 - $14.02 $420,547 - $925,600
-66,020 Reduced 50.72%
64,152 $873,000
Q1 2018

May 15, 2018

SELL
$3.72 - $7.64 $74,775 - $153,571
-20,101 Reduced 13.38%
130,172 $938,000
Q4 2017

Feb 14, 2018

BUY
$3.14 - $4.5 $289,847 - $415,386
92,308 Added 159.25%
150,273 $553,000
Q3 2017

Nov 14, 2017

BUY
$1.69 - $4.33 $97,960 - $250,988
57,965
57,965 $251,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.07B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.